BLGO ready for Nice Bounce After The Dip

  • The COVID-19 pandemic is causing unprecedented demand for disinfectants. The pandemic is also creating a critical shortage of masks and PPE that could be alleviated if there were a disinfection spray that was proven SAFE and able to inactivate SARS-CoV-2
  • The most common disinfectant used against SARS-CoV-2 is bleach, however, it must be diluted and its use must be limited because it can be corrosive and cause harm to the skin, eyes, and lungs
  • CDC reports calls to poison centers due to cleaning and disinfectant exposures increased by 20% in early 2020
  • Testing under the supervision of Dr. Slobodan Paessler, DVM, PhD at the Galveston National Laboratory at the University of Texas Medical Branch found Clyraguard, a novel iodine that is odorless and colorless to completely inactivate SARS-CoV-2 virus in laboratory testing
  • BioLargo’s subsidiary, Clyra Medical, is launching Clyraguard, an FDA cleared and registered disinfecting Personal Protection Spray for masks and Personal Protection Equipment that is safe on skin – recently highlighted on NBC – 2 news, Ft. Meyers, Florida
  • Galveston National Laboratory also tested and found BioLargo’s novel, odorless, colorless, iodine complex, CupriDyne, effective at inactivating SARS-CoV-2, and the report concludes strong evidence of the potential suitability of CupriDyne for minimizing environmental exposure to the SARS-CoV-2 by mass spraying to common surfaces
  • Because of unprecedented safety and proven efficacy, BioLargo’s  (BLGO) CupriDyne and Clyraguard have the potential to become blockbuster products in very large markets. In recent interview, CEO revealed current discussions with interested potential partners have expressed the need for up to millions of units per month
  • BioLargo shares are $0.17 with current market capitalization of $29 million


Read more from source 

Total Views: 569 ,